Leukemia, Myeloid, Acute: all 3,035 studies
Page 7 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.
- A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid LeukemiaRecruitingNCT05189639
- Niclosamide in Pediatric Patients With Relapsed and Refractory AMLRecruitingNCT05188170Phase 1
- Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AMLRecruitingNCT05184842Phase 2Results posted
- Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)RecruitingNCT05183035Phase 3
- Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone DensitometryNot yet recruitingNCT05161026Not applicable
- CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)RecruitingNCT05143996Phase 1
- A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeRecruitingNCT05140811Phase 1/2
- A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AMLRecruitingNCT05133882Phase 1/2
- Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic PathwaysRecruitingNCT05124288
- PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AMLRecruitingNCT05105152Phase 1
- Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and EfficacyRecruitingNCT05101551Phase 1
- Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological MalignancesRecruitingNCT05092451Phase 1/2
- Two Step Haplo With Radiation ConditioningRecruitingNCT05031897Phase 2
- Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05023707Phase 1/2
- TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid LeukemiaRecruitingNCT05017883Not applicable
- Backtracking Leukemia-Typical Somatic Mutations in Cord BloodRecruitingNCT05014165
- Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionRecruitingNCT05010772Phase 1
- ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT05010122Phase 1/2
- Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell TransplantationRecruitingNCT05005299Phase 1
- Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid LeukemiaRecruitingNCT05000801Not applicable
- (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisRecruitingNCT04996875Phase 2
- Phase IB/II of CPX-351 for Relapse Prevention in AMLRecruitingNCT04990102Phase 1/2
- Bisantrene Combination for Resistant AMLRecruitingNCT04989335Phase 2
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)RecruitingNCT04988555Phase 1/2
- Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDSRecruitingNCT04986657Not applicable
- Cardioprotection in AMLRecruitingNCT04977180Phase 2
- A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)RecruitingNCT04964518Phase 1/2
- Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic ImpairmentRecruitingNCT04953910Phase 1
- Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal ImpairmentRecruitingNCT04953897Phase 1
- Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AMLRecruitingNCT04913922Phase 2
- Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent FailureRecruitingNCT04905810Phase 2
- Methods of T Cell Depletion Trial (MoTD)RecruitingNCT04888741Phase 2
- Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPALRecruitingNCT04872478Phase 1
- Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell TransplantEnrolling by invitationNCT04836390Phase 2
- Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsRecruitingNCT04797767Phase 1/2
- Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)RecruitingNCT04777916
- Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT04774393Phase 1/2
- Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.RecruitingNCT04771572Phase 1
- A Study of BGB-11417 in Participants With Myeloid MalignanciesRecruitingNCT04771130Phase 1/2
- The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group StudyRecruitingNCT04726241Phase 1/2
- Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT04716452Phase 1
- A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-MutatedRecruitingNCT04716114Phase 3
- Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSRecruitingNCT04708054Phase 2/3
- Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)RecruitingNCT04707300Phase 1/2
- IS-free Treg HaploHCTRecruitingNCT04678401Phase 1
- CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic DiseasesRecruitingNCT04662294Early Phase 1
- Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid LeukemiaRecruitingNCT04659616Phase 1
- NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid LeukemiaNot yet recruitingNCT04658004Early Phase 1
- National Longitudinal Cohort of Hematological DiseasesRecruitingNCT04645199
- Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant DisordersRecruitingNCT04644016Phase 2
- Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2RecruitingNCT04628026Phase 3
- Pharmacokinetics of Venetoclax in Patients With Acute Myeloid LeukemiaRecruitingNCT04613622
- IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid LeukemiaNot yet recruitingNCT04599543Early Phase 1
- Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLRecruitingNCT04588922Phase 1/2
- Study to Evaluate the Safety and Tolerability of EP0042RecruitingNCT04581512Phase 1/2
- Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AMLRecruitingNCT04501120Phase 1/2
- CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04493164Phase 2
- A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid LeukemiaRecruitingNCT04471064Phase 1
- Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid NeoplasmsRecruitingNCT04460950
- Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)RecruitingNCT04385290Phase 1/2
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaRecruitingNCT04375631Phase 1
- Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia PatientsRecruitingNCT04314219Phase 3
- Genetic and Molecular Characteristics of Mexican Adults With Acute Myeloid Leukemia: a Prospective Multicentric Study.Not yet recruitingNCT04311060
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingNCT04293562Phase 3
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingNCT04282187Phase 2
- A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.RecruitingNCT04275518Phase 1
- Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT04272125Phase 1/2
- CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 ExpressionRecruitingNCT04257175Phase 2/3
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)RecruitingNCT04256317Phase 2/3
- A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04243785Phase 1
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesRecruitingNCT04195633Phase 2
- Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AMLRecruitingNCT04168502Phase 3
- Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02RecruitingNCT04167696Phase 1
- Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative NeoplasmRecruitingNCT04140487Phase 1/2
- A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)Enrolling by invitationNCT04093570Phase 2
- Precision Exercise in Children With Malignant HemopathiesRecruitingNCT04090268Not applicable
- Study to Evaluate CCS1477 (Inobrodib) in Haematological MalignanciesRecruitingNCT04068597Phase 1/2
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationRecruitingNCT04065399Phase 1/2
- CLAG-GO for Patients With Persistent, Relapsed or Refractory AMLRecruitingNCT04050280Phase 2
- Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After InductionRecruitingNCT04049539Phase 1/2
- Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingNCT04047641Phase 1/2
- Multi-CAR T Cell Therapy Targeting CD7-positive MalignanciesNot yet recruitingNCT04033302Phase 1/2
- A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell TransplantationRecruitingNCT04024761Phase 1
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)RecruitingNCT03970096Phase 2
- Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) TransplantRecruitingNCT03964506Early Phase 1
- Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid TumorsRecruitingNCT03934372Phase 1/2
- Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell TransplantRecruitingNCT03921047
- CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)RecruitingNCT03896854Phase 1/2
- Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT03874052Phase 1
- Longitudinal Studies of Patient With FPDMMRecruitingNCT03854318
- Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT03850574Phase 1/2
- PTX3-targeted Antifungal ProphylaxisRecruitingNCT03828773Not applicable
- Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute LeukemiaRecruitingNCT03826992Phase 1
- CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCTRecruitingNCT03810196Not applicable
- A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesRecruitingNCT03802695Phase 1
- Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCTRecruitingNCT03793517Phase 2/3
- Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid LeukemiaRecruitingNCT03737955Phase 2
- Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationRecruitingNCT03683433Phase 2
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic SyndromeRecruitingNCT03670966Phase 1/2
- Venetoclax RegistryRecruitingNCT03662724